Clinical Trial Update: A Multicenter, Non-interventional, Descriptive Study to Assess Assay Concordance of HER2 IHC Testing in Chinese Pan-tumor Patients

View source ↗

Summary

AstraZeneca is conducting a multicenter, non-interventional study in Chinese pan-tumor patients to assess concordance of HER2 IHC testing across multiple cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Gynecologic Cancer
• Non-small Cell Lung Cancer
• Urothelial Carcinoma

Snippet

Sponsor: AstraZeneca | Conditions: Pan-tumor(NSCLC, GYN Cancers, BTC and UC) | Status: RECRUITING